Erasca Investors Alert: Lawsuit Deadline Approaches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Lawsuit Reminder: The Law Offices of Howard G. Smith remind investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to file a lead plaintiff motion by August 10, 2026, to participate in the ongoing securities fraud lawsuit against the company.
- Stock Price Drop: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, to close at $19.15 per share after receiving a patent infringement allegation from Revolution Medicines, Inc., resulting in significant losses for investors.
- Clinical Data Disclosure: On the same day, Erasca reported preliminary Phase 1 clinical data for ERAS-0015, revealing a patient death approximately one month after treatment initiation, causing the stock price to plummet by $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, further exacerbating investor losses.
- False Statements Allegation: The lawsuit alleges that throughout the Class Period, Erasca failed to disclose critical adverse facts regarding ERAS-0015, particularly that its preclinical data was improperly compared to Revolution Medicines, misleading investors about the company's business prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 13.380
Low
2.00
Averages
5.50
High
11.00
Current: 13.380
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Investors Alert: Lawsuit Deadline Approaches
- Lawsuit Reminder: The Law Offices of Howard G. Smith remind investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to file a lead plaintiff motion by August 10, 2026, to participate in the ongoing securities fraud lawsuit against the company.
- Stock Price Drop: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, to close at $19.15 per share after receiving a patent infringement allegation from Revolution Medicines, Inc., resulting in significant losses for investors.
- Clinical Data Disclosure: On the same day, Erasca reported preliminary Phase 1 clinical data for ERAS-0015, revealing a patient death approximately one month after treatment initiation, causing the stock price to plummet by $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, further exacerbating investor losses.
- False Statements Allegation: The lawsuit alleges that throughout the Class Period, Erasca failed to disclose critical adverse facts regarding ERAS-0015, particularly that its preclinical data was improperly compared to Revolution Medicines, misleading investors about the company's business prospects.
See More
Erasca Faces Class Action Lawsuit Over Patent Violations
- Stock Price Plunge: Erasca's stock price plummeted approximately 53.9%, losing $11.59 per share from $21.49 to $9.90 after the revelation of improper preclinical data, indicating a severe crisis in market trust and significant losses for investors.
- Lawsuit Allegations: The class action lawsuit alleges that Erasca engaged in improper comparisons with Revolution Medicines' RMC-6236, potentially leading to patent infringement and trade secret misappropriation, with management failing to disclose these risks to investors, exacerbating investor concerns.
- Financing Motivation: The lawsuit claims that Erasca's $258.8 million stock offering on January 23, 2026, was aimed at maintaining an artificially inflated stock price, coinciding with management's repeated controversial comparisons at the J.P. Morgan Healthcare Conference, suggesting awareness of the vulnerability of these claims.
- Investor Rights: Investors are informed that those who purchased Erasca shares between January 14, 2025, and April 26, 2026, and suffered losses may be eligible to join the lawsuit, highlighting the critical importance of preclinical data disclosure obligations in the oncology sector.
See More
Erasca Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has filed a class action against Erasca, Inc. on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026, with a deadline for lead plaintiff motions set for August 10, 2026, highlighting the urgency of legal action.
- Legal Rights Consultation: Investors are encouraged to contact attorney Lesley F. Portnoy at 310-692-8883 or via email at lesley@portnoylaw.com for consultations on their legal rights and complimentary case evaluations, demonstrating the firm's commitment to investor protection.
- Details of Allegations: The complaint alleges that Erasca and certain executives failed to disclose material information during the class period, violating federal securities laws, specifically regarding improper comparisons of preclinical data for the ERAS-0015 product, which could jeopardize patent and trade secret protections, thereby impacting investor confidence.
- Historical Compensation Record: The founding partner of the Portnoy Law Firm has recovered over $5.5 billion for aggrieved investors, indicating the firm's capability and commitment to securing justice for investors, although past results do not guarantee future outcomes.
See More
Erasca Class Action Lawsuit Initiated
- Class Action Notification: Purchasers of Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to apply as lead plaintiff in a class action lawsuit alleging violations of the Securities Exchange Act by the company and its executives.
- Details of Allegations: The lawsuit claims that Erasca made misleading statements regarding its product ERAS-0015's preclinical data, which was improperly compared to Revolution Medicines, potentially risking patent and trade secret violations, thereby impacting the company's reputation and stock price.
- Stock Price Impact: Following the April 27, 2026, disclosure of a patent infringement letter from Revolution Medicines, Erasca's stock price fell nearly 11%, and after reporting preliminary Phase I clinical data, the stock plummeted over 48%, indicating significant market concerns about the company's future.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Erasca stock during the class period can seek to be appointed as lead plaintiff, representing the interests of other investors and influencing potential future recoveries.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, representing investors who purchased shares between January 14, 2025, and April 26, 2026, reflecting strong investor dissatisfaction with potential misleading statements made by the company.
- Intellectual Property Dispute: Despite assurances on March 12, 2026, regarding the protection of ERAS-0015's intellectual property, Erasca is accused of improper comparisons with competitor therapies, exposing the company to potential legal liabilities and undermining investor trust.
- Patient Adverse Event: Following market reactions, Erasca disclosed that a patient treated with ERAS-0015 suffered an adverse event and died a month later, intensifying investor scrutiny over the safety of its product and potentially impacting future research and market confidence.
See More
Class Action Lawsuit Announced for Erasca, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Erasca (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, with a deadline of August 10, 2026, for those wishing to serve as lead plaintiff, potentially allowing for compensation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements regarding its lead oncology drug candidate, ERAS-0015, throughout the class period, resulting in investor losses.
- Potential Compensation Mechanism: Investors joining the class action will not incur out-of-pocket fees, as attorney costs will be covered through a contingency fee arrangement, thereby reducing financial barriers and encouraging broader participation from affected investors.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its extensive experience and success in handling similar cases, which enhances investor confidence in their representation.
See More
Erasca Investors Alert: Lawsuit Deadline Approaches
- Lawsuit Reminder: The Law Offices of Howard G. Smith remind investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to file a lead plaintiff motion by August 10, 2026, to participate in the ongoing securities fraud lawsuit against the company.
- Stock Price Drop: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, to close at $19.15 per share after receiving a patent infringement allegation from Revolution Medicines, Inc., resulting in significant losses for investors.
- Clinical Data Disclosure: On the same day, Erasca reported preliminary Phase 1 clinical data for ERAS-0015, revealing a patient death approximately one month after treatment initiation, causing the stock price to plummet by $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, further exacerbating investor losses.
- False Statements Allegation: The lawsuit alleges that throughout the Class Period, Erasca failed to disclose critical adverse facts regarding ERAS-0015, particularly that its preclinical data was improperly compared to Revolution Medicines, misleading investors about the company's business prospects.
See More
Erasca Faces Class Action Lawsuit Over Patent Violations
- Stock Price Plunge: Erasca's stock price plummeted approximately 53.9%, losing $11.59 per share from $21.49 to $9.90 after the revelation of improper preclinical data, indicating a severe crisis in market trust and significant losses for investors.
- Lawsuit Allegations: The class action lawsuit alleges that Erasca engaged in improper comparisons with Revolution Medicines' RMC-6236, potentially leading to patent infringement and trade secret misappropriation, with management failing to disclose these risks to investors, exacerbating investor concerns.
- Financing Motivation: The lawsuit claims that Erasca's $258.8 million stock offering on January 23, 2026, was aimed at maintaining an artificially inflated stock price, coinciding with management's repeated controversial comparisons at the J.P. Morgan Healthcare Conference, suggesting awareness of the vulnerability of these claims.
- Investor Rights: Investors are informed that those who purchased Erasca shares between January 14, 2025, and April 26, 2026, and suffered losses may be eligible to join the lawsuit, highlighting the critical importance of preclinical data disclosure obligations in the oncology sector.
See More
Erasca Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has filed a class action against Erasca, Inc. on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026, with a deadline for lead plaintiff motions set for August 10, 2026, highlighting the urgency of legal action.
- Legal Rights Consultation: Investors are encouraged to contact attorney Lesley F. Portnoy at 310-692-8883 or via email at lesley@portnoylaw.com for consultations on their legal rights and complimentary case evaluations, demonstrating the firm's commitment to investor protection.
- Details of Allegations: The complaint alleges that Erasca and certain executives failed to disclose material information during the class period, violating federal securities laws, specifically regarding improper comparisons of preclinical data for the ERAS-0015 product, which could jeopardize patent and trade secret protections, thereby impacting investor confidence.
- Historical Compensation Record: The founding partner of the Portnoy Law Firm has recovered over $5.5 billion for aggrieved investors, indicating the firm's capability and commitment to securing justice for investors, although past results do not guarantee future outcomes.
See More
Erasca Class Action Lawsuit Initiated
- Class Action Notification: Purchasers of Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to apply as lead plaintiff in a class action lawsuit alleging violations of the Securities Exchange Act by the company and its executives.
- Details of Allegations: The lawsuit claims that Erasca made misleading statements regarding its product ERAS-0015's preclinical data, which was improperly compared to Revolution Medicines, potentially risking patent and trade secret violations, thereby impacting the company's reputation and stock price.
- Stock Price Impact: Following the April 27, 2026, disclosure of a patent infringement letter from Revolution Medicines, Erasca's stock price fell nearly 11%, and after reporting preliminary Phase I clinical data, the stock plummeted over 48%, indicating significant market concerns about the company's future.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Erasca stock during the class period can seek to be appointed as lead plaintiff, representing the interests of other investors and influencing potential future recoveries.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, representing investors who purchased shares between January 14, 2025, and April 26, 2026, reflecting strong investor dissatisfaction with potential misleading statements made by the company.
- Intellectual Property Dispute: Despite assurances on March 12, 2026, regarding the protection of ERAS-0015's intellectual property, Erasca is accused of improper comparisons with competitor therapies, exposing the company to potential legal liabilities and undermining investor trust.
- Patient Adverse Event: Following market reactions, Erasca disclosed that a patient treated with ERAS-0015 suffered an adverse event and died a month later, intensifying investor scrutiny over the safety of its product and potentially impacting future research and market confidence.
See More
Class Action Lawsuit Announced for Erasca, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Erasca (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, with a deadline of August 10, 2026, for those wishing to serve as lead plaintiff, potentially allowing for compensation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements regarding its lead oncology drug candidate, ERAS-0015, throughout the class period, resulting in investor losses.
- Potential Compensation Mechanism: Investors joining the class action will not incur out-of-pocket fees, as attorney costs will be covered through a contingency fee arrangement, thereby reducing financial barriers and encouraging broader participation from affected investors.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its extensive experience and success in handling similar cases, which enhances investor confidence in their representation.
See More
